JP2015513535A5 - - Google Patents

Download PDF

Info

Publication number
JP2015513535A5
JP2015513535A5 JP2014558090A JP2014558090A JP2015513535A5 JP 2015513535 A5 JP2015513535 A5 JP 2015513535A5 JP 2014558090 A JP2014558090 A JP 2014558090A JP 2014558090 A JP2014558090 A JP 2014558090A JP 2015513535 A5 JP2015513535 A5 JP 2015513535A5
Authority
JP
Japan
Prior art keywords
inhibitor
phosphatidylserine
use according
receptor
tim
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014558090A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015513535A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/053391 external-priority patent/WO2013124327A1/en
Publication of JP2015513535A publication Critical patent/JP2015513535A/ja
Publication of JP2015513535A5 publication Critical patent/JP2015513535A5/ja
Pending legal-status Critical Current

Links

JP2014558090A 2012-02-21 2013-02-20 ウイルス侵入補助因子としてのtimレセプター Pending JP2015513535A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12305193 2012-02-21
EP12305193.0 2012-02-21
EP12306281.2 2012-10-17
EP12306281 2012-10-17
PCT/EP2013/053391 WO2013124327A1 (en) 2012-02-21 2013-02-20 Tim receptors as virus entry cofactors

Publications (2)

Publication Number Publication Date
JP2015513535A JP2015513535A (ja) 2015-05-14
JP2015513535A5 true JP2015513535A5 (enExample) 2016-03-10

Family

ID=47739275

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014558090A Pending JP2015513535A (ja) 2012-02-21 2013-02-20 ウイルス侵入補助因子としてのtimレセプター

Country Status (7)

Country Link
US (1) US20160017035A1 (enExample)
EP (1) EP2817327A1 (enExample)
JP (1) JP2015513535A (enExample)
BR (1) BR112014021068A8 (enExample)
IN (1) IN2014DN07023A (enExample)
MX (1) MX2014010016A (enExample)
WO (1) WO2013124327A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013124324A1 (en) 2012-02-21 2013-08-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Tam receptors as virus entry cofactors
US11116818B2 (en) * 2012-12-13 2021-09-14 Children's Medical Center Corporation Dana-Farber Cancer Institute Compositions and methods for inhibiting viral entry
US20170000849A1 (en) * 2013-12-20 2017-01-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Cd300a receptors as virus entry cofactors
WO2016059146A1 (en) * 2014-10-15 2016-04-21 Annexin Pharmaceuticals Ab Therapeutic composition comprising annexin v
CN113980089B (zh) * 2014-12-05 2024-12-27 富士胶片株式会社 一种检测试样中的细胞外膜囊泡的方法和检测用试剂盒的用途
TWI895621B (zh) 2016-05-27 2025-09-01 美商艾吉納斯公司 抗-tim-3抗體及其使用方法
EP4512829A3 (en) 2016-07-14 2025-06-11 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
US20210024582A1 (en) * 2018-03-29 2021-01-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric tim-3 fusion protein
US11197910B1 (en) * 2020-08-19 2021-12-14 Vitruviae LLC Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases
CN119639892A (zh) * 2024-11-13 2025-03-18 浙江大学 一种分子标志物tim1及其在卵巢透明细胞癌中的应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08500481A (ja) 1992-05-11 1996-01-23 リボザイム・ファーマシューティカルズ・インコーポレーテッド ウイルスの複製を阻害するための方法および薬剤
US6620805B1 (en) 1996-03-14 2003-09-16 Yale University Delivery of nucleic acids by porphyrins
DE69727384T2 (de) 1996-05-24 2004-11-04 IC-VEC Ltd. Polykatonische sterin-derivate zur transfektion
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US6001311A (en) 1997-02-05 1999-12-14 Protogene Laboratories, Inc. Apparatus for diverse chemical synthesis using two-dimensional array
US20030229040A1 (en) 1997-03-21 2003-12-11 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
CA2289702C (en) 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
JP2002510319A (ja) 1997-07-01 2002-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
US20030073640A1 (en) 1997-07-23 2003-04-17 Ribozyme Pharmaceuticals, Inc. Novel compositions for the delivery of negatively charged molecules
JP2001510808A (ja) 1997-07-24 2001-08-07 イネックス ファーマシューティカルズ コーポレイション 核酸触媒の供給のためのリポソーム組成物
AU3751299A (en) 1998-04-20 1999-11-08 Ribozyme Pharmaceuticals, Inc. Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
US7112337B2 (en) 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
US7098032B2 (en) 2001-01-02 2006-08-29 Mirus Bio Corporation Compositions and methods for drug delivery using pH sensitive molecules
US20050037086A1 (en) 1999-11-19 2005-02-17 Zycos Inc., A Delaware Corporation Continuous-flow method for preparing microparticles
EP1292285A4 (en) 2000-06-02 2009-07-22 Eisai Corp North America SYSTEMS FOR DISPENSING BIOACTIVE AGENTS
US7427394B2 (en) 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US20020192274A1 (en) 2001-03-26 2002-12-19 Ponnappa Biddanda C. pH sensitive liposomal drug delivery
CN1294991C (zh) 2001-03-26 2007-01-17 阿尔扎公司 用于改善治疗物质的细胞内传递的脂质体组合物
US20030026831A1 (en) 2001-04-20 2003-02-06 Aparna Lakkaraju Anionic liposomes for delivery of bioactive agents
EP1383480A4 (en) 2001-04-30 2006-05-24 Targeted Genetics Corp Lipid-Containing Drug Delivery Complexes and Method of Producing the Same
DE10127526A1 (de) 2001-05-31 2002-12-12 Novosom Ag Verfahren zur Herstellung und Auflösung von Nano- und Mikrokapseln
US7101995B2 (en) 2001-08-27 2006-09-05 Mirus Bio Corporation Compositions and processes using siRNA, amphipathic compounds and polycations
DE10152145A1 (de) 2001-10-19 2003-05-22 Novosom Ag Stabilisierung von Liposomen und Emulsionen
EP2325193A3 (en) 2001-11-02 2012-05-02 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of RNA interference
AU2002359892A1 (en) 2001-12-31 2003-07-24 Elan Pharmaceuticals, Inc. Efficient nucleic acid encapsulation into medium sized liposomes
WO2003066069A1 (en) 2002-02-01 2003-08-14 Intradigm Corporation Polymers for delivering peptides and small molecules in vivo
US20050222064A1 (en) 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
US20040087024A1 (en) 2002-02-22 2004-05-06 Insert Therapeutics, Inc. Carbohydrate-modified polymers, compositions and uses related thereto
US7037520B2 (en) 2002-03-22 2006-05-02 Baylor College Of Medicine Reversible masking of liposomal complexes for targeted delivery
WO2003083443A2 (en) 2002-03-29 2003-10-09 University Of Florida Lipid mediated screening of drug candidates for identification of active compounds
WO2003099225A2 (en) 2002-05-24 2003-12-04 Mirus Corporation Compositions for delivering nucleic acids to cells
US7682626B2 (en) 2003-02-07 2010-03-23 Roche Madison Inc. Polyvinylethers for delivery of polynucleotides to mammalian cells
WO2009001224A2 (en) 2007-06-22 2008-12-31 Eth Zurich Antivirals
WO2009062112A2 (en) 2007-11-09 2009-05-14 The Salk Institute For Biological Studies Use of tam receptor inhibitors as antimicrobials
JP5590621B2 (ja) 2008-10-17 2014-09-17 ロンドン ヘルス サイエンシーズ センター リサーチ インコーポレイテッド 炎症性障害の処置を処置するためのアネキシンおよびその使用
JP2013532153A (ja) * 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのtim−3およびpd−1に対する二重特異性抗体
WO2013124324A1 (en) 2012-02-21 2013-08-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Tam receptors as virus entry cofactors

Similar Documents

Publication Publication Date Title
JP2015513535A5 (enExample)
WO2015042308A3 (en) Rna-based hiv inhibitors
JP2014519662A5 (enExample)
JP2012126742A5 (enExample)
JP2013172734A5 (enExample)
MX2015000116A (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos.
JP2015526391A5 (enExample)
EP4632075A3 (en) Method for reducing immunogenicity of rna
JP2014513356A5 (enExample)
BRPI0813237B8 (pt) composto, método para preparar o composto, medicamento, e, uso do composto
JP2015521593A5 (enExample)
JP2017070307A5 (enExample)
JP2011528896A5 (enExample)
JP2013539454A5 (enExample)
PH12014501628A1 (en) Stabilized formulations containing anti-ang2 antibodies
FI3581650T3 (fi) IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
WO2013006795A3 (en) Antiviral compositions and methods of their use
JP2011172579A5 (enExample)
JP2018510132A5 (enExample)
BR112013002296A2 (pt) composição farmacêutica e respectivo uso e método para tratar doença infecciosa
JP2013503110A5 (enExample)
MX2010002018A (es) Peptido de cdh3 y agente medicinal que comprende al mismo.
JP2014503593A5 (enExample)
EA201592185A1 (ru) 4'-азидо, 3'-дезокси-3'-фторзамещенные нуклеозидные производные
JP2015523858A5 (enExample)